Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho to Draw Conclusion on Drug Pricing System Reform in 2009: Mr Kinoshita
January 26, 2009
- Inhibition of BDNF by Stress Hormones Shown by NCNP/NIN Research Team
January 26, 2009
- Diovan Remains Number One: Rep Track Survey
January 26, 2009
- Jansen: Intelence for HIV-1 Infection
January 26, 2009
- BUSINESS NEWS IN BRIEF
January 26, 2009
- Sato Enters the Field of Diagnostic Agents
January 26, 2009
- Nichi-Iko Aims at Entering Global Top-10 Club in 2012: President Tamura
January 26, 2009
- 3,030 Reports on Device Malfunctions Received in 1st Half of FY2008
January 26, 2009
- JGA to Demand Fixed Sum Price Adjustment Range for Low-Priced Generics
January 26, 2009
- Kaken: Hand-Sized Seprafilm
January 26, 2009
- R&D of Micellar Anticancer Drugs Progresses at Nippon Kayaku
January 19, 2009
- Sato Pharm Launches Thyrogen to Aid in Thyroid Cancer Diagnosis
January 19, 2009
- Toho to Acquire Omwell
January 19, 2009
- SELF-MEDICATION NEWS IN BRIEF
January 19, 2009
- All Stakeholders' Cooperation Essential to Further Improve Distribution Business Practices: Mr Matsutani
January 19, 2009
- Why Seeds of Success Sprout from the Problem
January 19, 2009
- 52 Zensharen Hospitals Start Jointly Purchasing Drugs
January 19, 2009
- 4 Biologics Now Available in Japan for RA
January 19, 2009
- JPA to Watch Development in Niigata Prefecture
January 19, 2009
- Consider Expansion of Application of DRG/PPS: Council
January 19, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…